Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

LAGOON and IMFORTE Trials: Data Updates and Expert Insights

August 7th 2023

A review of the LAGOON and IMFORTE trials with expert insights regarding the potential clinical implications of current and future study findings.

Dr Doroshow on RET Inhibitors in RET Fusion+ NSCLC

August 4th 2023

Deborah B. Doroshow, MD, PhD, discusses the similarities and differences between the efficacy and safety profiles of pralsetinib and selpercatinib in patients with non–small cell lung cancer harboring RET fusions.

Dr Massarelli on NTRK Inhibitors in NTRK Fusion+ NSCLC

August 4th 2023

Erminia Massarelli MD, PhD, MS, discusses efficacy and safety data with the NTRK inhibitors larotrectinib and entrectinib in patients with non–small cell lung cancer harboring NTRK fusions.

Zipalertinib Plus Chemotherapy Moves to Phase 3 Study in EGFR Exon 20 Insertion+ NSCLC

August 4th 2023

The safety and efficacy of zipalertinib plus platinum-based chemotherapy will be compared with platinum-based chemotherapy alone in patients with treatment-naïve, locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations in the phase 3 REZILIENT3 trial.

Dr Wakelee on Key Trials With Perioperative Immunotherapy in Early-Stage NSCLC

August 4th 2023

Heather Wakelee, MD, FASCO, discusses the clinical significance of updated data from several key trials evaluating perioperative immunotherapy in early-stage non–small cell lung cancer.

Selpercatinib Meets PFS End Point in Newly Diagnosed Advanced or Metastatic RET+ NSCLC

August 4th 2023

Selpercatinib significantly improved progression-free survival vs platinum-based chemotherapy plus pemetrexed and pembrolizumab in patients with advanced or metastatic non–small cell lung cancer harboring RET fusions.

Stereotactic Ablative Body Radiotherapy Yields Long-Term Disease Control in Lung Oligometastases Regardless of Fractionation Schedule

August 4th 2023

Single-fraction stereotactic ablative body radiotherapy generated overall survival outcomes comparable to those achieved with multifraction SABR in patients with lung oligometastases.

Dr Kim on the Bridging the Gaps in Lung Cancer Meeting

August 3rd 2023

Edward S. Kim, MD, MBA, discusses the importance of the Bridging the Gaps in Lung Cancer meeting, and expands on the importance of educating clinicians on how to best implement new developments within lung cancer to address these gaps in care.

Practice Pearls for Community Oncologists Treating Early-Stage NSCLC

August 3rd 2023

A panel of experts share unmet needs and clinical practice pearls for community oncologists regarding the treatment of patients with early-stage NSCLC.

Treatment for Patients Unsuitable for or Refractory to Consolidation Durvalumab

August 3rd 2023

Tina Cascone, MD, Ben Levy, MD, and Sandip Patel, MD, offer insights into the treatment approach in patients with unresectable early-stage NSCLC who are unsuitable for consolidation durvalumab or who progress on consolidation durvalumab.

Further Research May Delineate Immunotherapy Resistance Mechanisms in Lung Cancer

August 2nd 2023

Solange Peters, MD, PhD, discusses the successes and shortcomings of immunotherapy in patients with lung cancer; current challenges with defining resistance mechanisms to immunotherapy in this disease; and the potential applications of circulating tumor DNA monitoring in the early and metastatic disease settings.

Dr Das on the Landscape of Current and Emerging ADCs in SCLC

August 2nd 2023

Millie Das, MD, discusses the current landscape of new and emerging ADCs under investigation in small-cell lung cancer and highlights the phase 2 SWOG S1929 study.

Time to Treatment Initiation Affected by Demographics, Socioeconomics in Solid Tumors

August 2nd 2023

Delays in time to treatment initiation may be associated with demographic and socioeconomic disparities, with care coordination, clinical, and socioeconomic factors representing potential predictors of TTI, according to findings from a retrospective cohort study published in JCO Oncology Practice.

Zipalertinib Shows Antitumor Activity and a Manageable Safety Profile in EGFR Exon 20+ NSCLC

August 2nd 2023

Zipalertinib demonstrated promising efficacy as well as an acceptable safety profile in heavily pretreated patients with recurrent or metastatic non–small cell lung cancer with EGFR exon 20 insertions.

Small Cell Lung Cancer: What is the Role of Biomarker Testing?

July 31st 2023

Shared insight on the early but evolving role of biomarker testing in patients diagnosed with extensive- or limited-stage small cell lung cancer.

Current Strategies in Diagnosis and Classification of Small Cell Lung Cancer

July 31st 2023

Expert oncologists Laurent Greiller, MD, and Christian Grohé, MD, make introductions and review the current paradigm for small cell lung cancer diagnosis and classification.

Patient Scenario 3: 2L Lurbinectedin Following 1L Combination IO Chemotherapy

July 31st 2023

A panel of expert oncologists present the case of a 78-year-old woman who is treated with lurbinectedin following disease progress on first-line carboplatin, etoposide, and atezolizumab.

Evolving Treatment Strategies for SCLC in the Second-Line Setting and Beyond

July 31st 2023

Panel experts discuss evolving treatment options for small-cell lung cancer in the second-line setting and beyond.

Several Research Avenues Are Available for Improving Response to Immunotherapy in Advanced NSCLC

July 29th 2023

Tony S.K. Mok, MD, BMSc, FRCPC, FASCO, highlights novel partners and potential new approaches for immunotherapy-based regimens for the treatment of patients with non–small cell lung cancer.

ADCs Offer Exciting Potential in Lung Cancer

July 29th 2023

Antibody-drug conjugates represent one of the most exciting areas of ongoing development for the treatment of patients with non–small cell lung cancer and small cell lung cancer.